G-CSF for Fever and Neutropenia Induced by Chemotherapy

Publisher Website
Google Scholar
Abstract
As a clinical hematologist, I am glad to see granulocyte colony-stimulating factor (G-CSF) become available for clinical use. However, in view of a recent critique of the cost effectiveness of intravenous preparations of immune globulin in the treatment of chronic lymphocytic leukemia,1 I was surprised to see the Journal publish without editorial comment an article on G-CSF, by Crawford et al. (July 18 issue),2 containing the statement that in addition to the clinical impact of G-CSF, "there may be a substantial economic impact" — the implication being that the economic impact would be favorable in that the drug will prevent infections and hospitalizations.